Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Tango Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Highlights
Tango Therapeutics to Participate in Upcoming Investor Conferences
Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline
BOSTON, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision...
Tango Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medivir´s licensee, Tango Therapeutics, has dosed the first patient with TNG348
BOSTON, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision...
“ Data support the ongoing clinical development of TNG908 and TNG462 PRMT5 inhibitors for the treatment of MTAP-deleted cancers “ BOSTON, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Tango...
Dose escalation ongoing in phase 1/2 trials of lead PRMT5 inhibitors TNG908 and TNG462; additional TNG908 clinical data expected 2024 Dose escalation ongoing in phase 1/2 trial of CoREST...